CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Organon & Co is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Organon & Co
30 Hudson Street, Fl 33
Phone: (551) 430-6000p:551 430-6000 JERSEY CITY, NJ  07302  United States Ticker: OGNOGN
Business Summary
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Carrie S.Cox 66 1/1/2021 1/1/2021
Chief Executive Officer, Director KevinAli 64 1/1/2021 1/1/2021
Chief Financial Officer, Executive Vice President Matthew M.Walsh 57 1/1/2021 1/1/2021
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Forendo Pharma Oy Itinen Pitkkatu 4 B Turku Finland
Dermavant Sciences GmbH Viaduktstrasse 8 Basel BS Switzerland
Dermavant Sciences, Ltd. 3780 Kilroy Airport Way Long Beach CA United States

Business Names
Business Name
Alydia Health
Alydia Health, Inc.
AND SCIENTIFIC OFFICES
121 additional Business Names available in full report.

General Information
Number of Employees: 10,000 (As of 12/31/2023)
Outstanding Shares: 257,538,875 (As of 10/25/2024)
Shareholders: 69,973
Stock Exchange: NYSE
Federal Tax Id: 852269702
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024